Online inquiry

IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8358MR)

This product GTTS-WQ8358MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8358MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10382MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ15816MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3298MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ9484MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ13882MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ6041MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7928MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ3533MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW